S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   394.26 (-1.36%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   394.26 (-1.36%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   394.26 (-1.36%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   394.26 (-1.36%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
NASDAQ:LIFE

aTyr Pharma Stock Forecast, Price & News

$8.13
+0.22 (+2.78%)
(As of 11/30/2021 01:42 PM ET)
Add
Compare
Today's Range
$7.76
$8.14
50-Day Range
$7.91
$12.48
52-Week Range
$3.48
$13.10
Volume
4,674 shs
Average Volume
223,309 shs
Market Capitalization
$225.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51
30 days | 90 days | 365 days | Advanced Chart
Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.


aTyr Pharma logo

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline include ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1;DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Headlines

aTyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Update
November 19, 2021 |  americanbankingnews.com
-$0.34 EPS Expected for aTyr Pharma, Inc. (NASDAQ:LIFE) This Quarter
November 12, 2021 |  americanbankingnews.com
What 6 Analyst Ratings Have To Say About aTyr Pharma
November 11, 2021 |  markets.businessinsider.com
aTyr Pharma (NASDAQ:LIFE) PT Lowered to $11.00
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
42
Year Founded
2005

Sales & Book Value

Annual Sales
$10.45 million
Book Value
$2.86 per share

Profitability

Net Income
$-16.22 million
Pretax Margin
-1,468.63%

Debt

Price-To-Earnings

Miscellaneous

Free Float
26,363,000
Market Cap
$225.93 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/22/2022

Social Links


MarketRank

Overall MarketRank

2.42 out of 5 stars

Medical Sector

157th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

25th out of 202 stocks

Analyst Opinion: 4.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

Is aTyr Pharma a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" aTyr Pharma stock.
View analyst ratings for aTyr Pharma
or view top-rated stocks.

How has aTyr Pharma's stock been impacted by Coronavirus (COVID-19)?

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LIFE shares have increased by 166.7% and is now trading at $8.08.
View which stocks have been most impacted by COVID-19
.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a drop in short interest in October. As of October 29th, there was short interest totaling 793,800 shares, a drop of 34.4% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 5,350,000 shares, the short-interest ratio is presently 0.1 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for aTyr Pharma
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.11. During the same quarter in the prior year, the firm earned ($0.68) earnings per share.
View aTyr Pharma's earnings history
.

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

Shares of aTyr Pharma reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for LIFE?

7 brokerages have issued 12 month target prices for aTyr Pharma's stock. Their forecasts range from $11.00 to $22.00. On average, they anticipate aTyr Pharma's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 122.8% from the stock's current price.
View analysts' price targets for aTyr Pharma
or view top-rated stocks among Wall Street analysts.

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the following people:
  • Sanjay S. Shukla, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Jill M. Broadfoot, Chief Financial Officer
  • Leslie Nangle, Vice President-Research
  • Andrew B. Cubitt, Vice President-External Scientific Alliances
  • Ashlee Dunston, Director-Investor Relations & Communications

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma CEO Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among aTyr Pharma's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include VR Adviser LLC (9.25%), Tang Capital Management LLC (6.58%), Two Sigma Investments LP (3.20%), Two Sigma Advisers LP (2.85%), Stonepine Capital Management LLC (2.43%) and EAM Investors LLC (1.54%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends for aTyr Pharma
.

Which institutional investors are selling aTyr Pharma stock?

LIFE stock was sold by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., BlackRock Inc., and Millennium Management LLC. Company insiders that have sold aTyr Pharma company stock in the last year include Jill Marie Broadfoot, John K Clarke, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma
or view top insider-selling stocks.

Which institutional investors are buying aTyr Pharma stock?

LIFE stock was purchased by a variety of institutional investors in the last quarter, including VR Adviser LLC, Tang Capital Management LLC, Two Sigma Investments LP, Stonepine Capital Management LLC, Two Sigma Advisers LP, EAM Investors LLC, Citadel Advisors LLC, and EAM Global Investors LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, Paul Schimmel, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma
or or view top insider-buying stocks.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $8.08.

How much money does aTyr Pharma make?

aTyr Pharma has a market capitalization of $224.54 million and generates $10.45 million in revenue each year. The biotechnology company earns $-16.22 million in net income (profit) each year or ($2.04) on an earnings per share basis.

How many employees does aTyr Pharma have?

aTyr Pharma employs 42 workers across the globe.

When was aTyr Pharma founded?

aTyr Pharma was founded in 2005.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is www.atyrpharma.com.

Where are aTyr Pharma's headquarters?

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 731-8389, via email at [email protected], or via fax at 858-731-8394.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.